Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stabilized ophthalmic galactomannan formulations

a technology of galactomannan and formulation, which is applied in the field of ophthalmic formulations comprising galactomannans, can solve the problems of dramatic affecting the viscosity of such formulations, and achieve the effects of stabilizing the viscosity of such solutions, minimizing viscosity loss, and safe storag

Inactive Publication Date: 2011-11-10
ALCON RES LTD
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]Embodiments of the invention generally relate to ophthalmic formulations comprising galactomannan. The present inventors have unexpectedly discovered that diol alcohols can be included in such ophthalmic formulations to stabilize the viscosity of such solutions. The stabilization of the ophthalmic formulations by diol alcohols minimizes viscosity loss at elevated temperatures and ensures that the formulations can be stored safely for longer periods of time without viscosity loss.

Problems solved by technology

Also, ophthalmic formulations must be sterilized before use, and the sterilization process, particularly heat sterilization, can dramatically affect the viscosity of such formulations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0030]

Ingredient% w / vHydroxypropyl Guar Galactomannan0.25Boric Acid1.0Sorbitol1.0Polyethylene Glycol0.4Propylene Glycol0.3Potassium Chloride0.12Sodium Chloride0.35Polyquaternium-10.001 + 10% excess2-Amino-2-methylpropanol0.57Sodium Hydroxide / Hydrochloric Acidq.s. pH 7.9Purified Waterq.s. 100%

example 2

Formulation Studies

[0031]The viscosity of various solutions of the present invention and control solutions was evaluated using a controlled stress rheometer (AR 2000ex, TA Instruments, Inc.). The measurement system was a 40 mm acrylic 2° cone and plate with a sample volume of 0.58 mL. A temperature of 25° C. + / −0.1° C. was maintained and a cover was placed over the measurement system to prevent evaporation of the solutions.

[0032]Three variables were investigated in these experiments and the results summarized in Table 1 below. Solution 89A is the control for this experiment. The dissolved O2 level at ambient conditions is constant at 7 ppm. The initial viscosity of Solution 89A at a shear rate of 10s−1 is at 10.97 cP. After 5 weeks at room temperature, there is a small drop in viscosity of 3.65%. After 5 weeks at elevated temperatures of 40° C. there is a much greater drop in viscosity of 14.77%.

[0033]Solution 89B has the highest initial viscosity of the formulations tested. 89B is ...

example 3

Molecular Weight Studies

[0037]Native guar with a molecular weight of 3.0M Daltons manufactured according to the process described in U.S. Patent Application Publication No. 2010 / 0196415 (previously incorporated by reference) was formulated in test formulations A-C set forth in Table 4 below. Following sterilization by autoclaving, the molecular weight of native guar in each formulation was measured. Compared to formulations B and C, the native guar in formulation A not containing a diol compound (sorbitol or glycerol) had a significantly lower measured molecular weight. The use of diol compounds in the guar formulations has a preservation effect on the molecular weight of guar during the sterilization process.

TABLE 4Summary of Molecular Weight StudyFormulation Chemical(% w / v)ABCNative Guar0.50.50.5Sorbitol—1—Glycerol——1Purified WaterQSQSQSpH888Native Guar Molecular Weight1.92.52.5after Autoclaving (M Daltons)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
osmolalityaaaaaaaaaa
osmolalityaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application No. 61 / 331,511, filed May 5, 2010, the entire contents of which are incorporated herein by reference.TECHNICAL FIELD OF THE INVENTION[0002]The present invention relates to ophthalmic formulations comprising galactomannans, and more specifically to formulations comprising galactomannan and a diol alcohol compound in a quantity sufficient to stabilize the viscosity of the formulation.BACKGROUND OF THE INVENTION[0003]Ophthalmic formulations often comprise compounds that provide desirable properties to the formulation. When these formulations are instilled in the eye, the properties of such compounds can help prevent ophthalmic problems such as bioadhesion and the formation of friction-induced tissue damage, as well as encourage the natural healing and restoration of previously damaged tissues.[0004]Formulations are typically developed with a target vi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/736A61P27/04
CPCA61K9/0048A61K45/06A61K31/736A61K9/08A61K47/10A61K47/26A61P27/02A61P27/04
Inventor KETELSON, HOWARD ALLENDAVIS, JAMES W.MEADOWS, DAVID L.
Owner ALCON RES LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com